Formycon AG

Formycon AG’s share sale by the Active Ownership Fund SICAV SIF SCS, led by supervisory‑board member Klaus Röhrig, signals a potential shift in investor confidence and may affect the biopharma firm’s stock and strategic outlook in the biosimilar mar…

Formycon AG faces market pressure after reporting a significant downturn in first-half revenues, but maintains an optimistic outlook for 2025 and reaffirms its 2025 guidance.

Formycon AG, a biopharmaceutical company, has seen significant stock price fluctuations, but early investors have reaped rewards, with a 5-year investment yielding a 35% return.

Formycon AG is navigating a challenging financial landscape, but remains optimistic about its future prospects in the biosimilar sector, despite a decline in revenue and market fluctuations.

Despite a significant decline in quarterly revenues, Formycon AG’s strategic foresight and operational tenacity position it for future growth in the rapidly expanding biosimilar market.